Literature DB >> 11091532

Clinical and Histological Prognostic Factors in Axillary Node-Negative BreastCancer: Univariate and Multivariate Analysis with Relation to 5-Year Recurrence.

.   

Abstract

In the recent years several studies have shown that about 30% of cases with axillary node-nagative breast cancer suffer relapse of the disease. Our attempt was made to evaluate the most significant prognostic factors to predict this high risk group which may be benefited from adjuvant treatment. For this purpose, we selected 9 patients out of 80 cases of node-negative breast cancer who had been followed up at least for 5 years and had the recurrence of the disease. For comparison, 16 patients from the same group who did not have relapse were selected on a random basis. Histology, receptor status, AgNOR, DNA flow cytometry and various immunohistochemical parameters were compared between the groups with recurrence and that without recurrence. On univariate analysis, tumor size, immunohistochemical expressions of PCNA, MIB-1, c-erbB-2 and S-phase fraction were significantly different between the above two groups. By multivariate analysis, immunohistochemical c-erbB-2 expression (more than 50% of cancer cells) was an independent parameter. As a summary from our studies, c-erbB-2 immunohistochemical staining on paraffin sections might be the best independent prognostic factor in axillary node-negative breast cancers.

Entities:  

Year:  1995        PMID: 11091532     DOI: 10.1007/BF02966896

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  29 in total

Review 1.  Monoclonal antibody Ki-67: its use in histopathology.

Authors:  D C Brown; K C Gatter
Journal:  Histopathology       Date:  1990-12       Impact factor: 5.087

2.  Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.

Authors:  E G Mansour; R Gray; A H Shatila; C K Osborne; D C Tormey; K W Gilchrist; M R Cooper; G Falkson
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

3.  Expression of the c-erbB-2 protein in normal and transformed cells.

Authors:  W J Gullick; M S Berger; P L Bennett; J B Rothbard; M D Waterfield
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

Review 4.  Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma.

Authors:  S S Bacus; S G Ruby
Journal:  Pathol Annu       Date:  1993

5.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

Authors:  D W Hedley; M L Friedlander; I W Taylor; C A Rugg; E A Musgrove
Journal:  J Histochem Cytochem       Date:  1983-11       Impact factor: 2.479

6.  Indicators of prognosis in node-negative breast cancer.

Authors:  H Sigurdsson; B Baldetorp; A Borg; M Dalberg; M Fernö; D Killander; H Olsson
Journal:  N Engl J Med       Date:  1990-04-12       Impact factor: 91.245

7.  A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.

Authors:  B Fisher; C Redmond; N V Dimitrov; D Bowman; S Legault-Poisson; D L Wickerham; N Wolmark; E R Fisher; R Margolese; C Sutherland
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

8.  Prognostic factors in node-negative breast cancer.

Authors:  H Johnson; S Masood; C Belluco; A M Abou-Azama; S Dee; L Kahn; L Wise
Journal:  Arch Surg       Date:  1992-12

9.  Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.

Authors: 
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

Review 10.  Nucleolar organiser regions in pathology.

Authors:  M J Egan; J Crocker
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.